-
-
Founded in 2016, Abbisko is an oncology-focused biopharmaceutical company, dedicated to discovering and developing innovative medicines to meet unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Abbisko has built an extensive pipeline of 15 innovative small molecule programs focused on precision oncology and immuno-oncology, including eight clinical stage assets.
LinkDoc is leading oncology big data company and has developed proprietary machine learning and human language processing enabled mechanism to structure millions of clinical EMR into research grade data. The Company has collaborated with over 600 departments from top 300 oncology centers in China.
Honor Trends utilizes Internet of Things (IoT), big data and cloud platform technologies to provide RFID hardware and software solutions for blood management and information management, and also provides enterprises with information system maintenance and consulting services, enabling clients to improve information management efficiency and security.
Abogen Biosciences is a leading biotech company dedicated to bringing an array of transformative therapies through the advancement of mRNA science and technology. Currently, the Company is progressing with its mature pipeline of mRNA-based therapeutics to tackle otherwise untreatable diseases in diversified therapeutic areas: infectious diseases, oncology and rare diseases.
Founded in 2015, Innogen is a science-driven biotechnology company dedicated to the research and development of innovative and affordable medicines for diabetes and other metabolic disease patients. Innogen’s deep pipeline in metabolic disease that includes Type 1 and Type 2 diabetes, obesity, NASH etc. is independently developed and has global market rights. Efsubaglutide Alfa (Former Name: Supaglutide), Innogen’s leading drug candidate, is a long-acting humanized GLP-1 receptor agonist. Currently under phase III trials for T2D, Efsubaglutide Alfae will be the first humanized long-acting GLP-1 drug that originated from China.
Simnova is a clinical stage biotech company focusing on the development of therapy for cancer treatment. It has a rich R&D pipeline, including both clinical and pre-clinical programs and is developing proprietary off-the-shelf CAR-NK and BiTE-armed CAR-T cell therapies.